WallStSmart

Insmed Inc (INSM)vsCentury Therapeutics Inc (IPSC)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Insmed Inc generates 456% more annual revenue ($606.42M vs $109.16M). INSM leads profitability with a -2.1% profit margin vs -8.8%. INSM earns a higher WallStSmart Score of 39/100 (F).

INSM

Hold

39

out of 100

Grade: F

Growth: 6.0Profit: 2.0Value: 6.7Quality: 6.3
Piotroski: 6/9Altman Z: -3.77

IPSC

Avoid

27

out of 100

Grade: F

Growth: 5.3Profit: 2.0Value: 5.0Quality: 5.0

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

INSM0 strengths · Avg: 0/10

No standout strengths identified

IPSC1 strengths · Avg: 10.0/10
Price/BookValuation
1.1x10/10

Reasonable price relative to book value

Areas to Watch

INSM4 concerns · Avg: 3.0/10
Revenue GrowthGrowth
1.5%4/10

1.5% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Price/BookValuation
43.0x2/10

Trading at 43.0x book value

Return on EquityProfitability
-2.5%2/10

ROE of -2.5% — below average capital efficiency

IPSC4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$434.93M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-6.0%2/10

ROE of -6.0% — below average capital efficiency

Revenue GrowthGrowth
-100.0%2/10

Revenue declined 100.0%

Comparative Analysis Report

WallStSmart Research

Bull Case : INSM

PEG of 1.09 suggests the stock is reasonably priced for its growth.

Bull Case : IPSC

The strongest argument for IPSC centers on Price/Book.

Bear Case : INSM

The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.

Bear Case : IPSC

The primary concerns for IPSC are EPS Growth, Market Cap, Return on Equity.

Key Dynamics to Monitor

IPSC carries more volatility with a beta of 1.72 — expect wider price swings.

INSM is growing revenue faster at 1.5% — sustainability is the question.

IPSC generates stronger free cash flow (-16M), providing more financial flexibility.

Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.

Bottom Line

INSM scores higher overall (39/100 vs 27/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Insmed Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.

Century Therapeutics Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Century Therapeutics Inc. (Ticker: IPSC) is a pioneering biotechnology company dedicated to advancing allogenic cell therapies that aim to revolutionize cancer treatment. Leveraging its proprietary induced pluripotent stem cell (iPSC) technology, the company is developing innovative off-the-shelf therapeutic solutions designed to improve both patient outcomes and accessibility. With a strong pipeline of clinical-stage product candidates and strategic collaborations enhancing its competitive advantage, Century Therapeutics is well-positioned to drive innovation in the rapidly expanding cell therapy landscape, presenting compelling potential for clinical breakthroughs and favorable shareholder returns.

Want to dig deeper into these stocks?